At a glance
ClinicalIndex Comparison RecordN/ACompleted· 21 enrolled
Drug / intervention
Buprenorphine Control +3 moredrug
Likely dose
Buprenorphine + Rifampin 600 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Influence of CYP3A Modulation on Buprenorphine Disposition and Clinical Effects
In Brief
A clinical study evaluating Buprenorphine Control, Buprenorphine + Rifampin, and 2 other interventions for Healthy. Completed, enrolled 21 participants across 1 site.
Detailed Summary
To evaluate role of CYP3A in buprenorphine disposition and effect
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2010
First PostedApr 2012
Primary CompletionMar 2014
TodayJul 2026
First PostedApr 12, 2012
Enrollment StartJun 1, 2010
Primary CompletionMar 29, 2014
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 14.2 years ago
Interventions
Buprenorphine Controldrug
Control (no pretreatment) - intravenous and sublingual buprenorphine. Some subjects will only undergo session 1 (IV)
Buprenorphine + Rifampindrug
Liver and gut CYP3A induction (rifampin 600 mg daily), intravenous and sublingual buprenorphine
Buprenorphine + Grapefruit juicedrug
Gut only CYP3A inhibition (grapefruit juice the night before), sublingual buprenorphine
Buprenorphine + Ketoconazoledrug
Liver and gut CYP3A inhibition (ketoconazole 400 mg daily), intravenous and sublingual buprenorphine